Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study

被引：10
作者：
Cao, Yanyan [1 ,2 ]
Ouyang, Tao [1 ,2 ]
Xiong, Fu [1 ,2 ]
Kan, Xuefeng [1 ,2 ]
Chen, Lei [1 ,2 ]
Liang, Bin [1 ,2 ]
Zheng, Chuansheng [1 ,2 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Wuhan 430022, Hubei, Peoples R China
[2] Hubei Prov Key Lab Mol Imaging, Wuhan 430022, Hubei, Peoples R China
来源：
HEPATOLOGY INTERNATIONAL | 2021年 / 15卷 / 05期
基金：
中国国家自然科学基金;
关键词：
Hepatocellular carcinoma (HCC); Apatinib; Sorafenib; Transarterial chemoembolization (TACE); Refractory; Supportive care; Combination treatment; Overall survival; Tumor response; Retrospective; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; PLACEBO;
D O I：
10.1007/s12072-021-10198-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Purpose To investigate the efficacy of sequential apatinib treatment in patients with unresectable hepatocellular carcinoma (HCC) refractory to sorafenib-transarterial chemoembolization (TACE). Materials and methods This respective study was conducted on 95 consecutive patients with sorafenib-TACE-refractory unresectable HCC in our center from January 2014 to December 2019. According to the response to sorafenib-TACE treatment and the subsequent management, the eligible patients were assigned into three groups: sorafenib-TACE (ST) group, sorafenib-TACE-apatinib (STA) group, and sorafenib-TACE-supportive care (STS) group. The differences in overall survival (OS) and tumor response were compared among the three groups. Risk factors related to prognosis were analyzed. Results A total of 58 patients were enrolled in the study, with 11, 15, and 28 patients in ST, STA, and STS group, respectively. The median OS of the STA group was significantly improved when compared with the STS group, either from the start of sorafenib-TACE resistance or the initiation of sorafenib-TACE therapy (14.0 versus 4.0 months, p = 0.003; 19.0 versus 9.0 months, p < 0.001; respectively). Additionally, from the start of sorafenib-TACE treatment, the median OS of the STA group was longer than that of the ST group without statistical difference (19.0 versus 15.0 months, p = 0.28), so did the comparison of median OS between the ST group and the STS group (15.0 versus 9.0 months, p = 0.06). Extrahepatic metastases were an independent risk factor for poor prognosis. Conclusion In patients with sorafenib-TACE-refractory HCC, subsequent apatinib treatment significantly improved the OS when compared with supportive care, and produced comparative outcomes with those sorafenib-TACE responders.
引用
收藏
页码：1268 / 1277
页数：10
相关论文
共 26 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2 [J].
Arizumi, Tadaaki ;
Minami, Tomohiro ;
Chishina, Hirokazu ;
Kono, Masashi ;
Takita, Masahiro ;
Yada, Norihisa ;
Hagiwara, Satoru ;
Minami, Yasunori ;
Ida, Hiroshi ;
Ueshima, Kazuomi ;
Kamata, Ken ;
Minaga, Kosuke ;
Komeda, Yoriaki ;
Takenaka, Mamoru ;
Sakurai, Toshiharu ;
Watanabe, Tomohiro ;
Nishida, Naoshi ;
Kudo, Masatoshi .
DIGESTIVE DISEASES, 2017, 35 (06) :589-597
[3]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[4]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[5]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[6]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
[7]   Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial [J].
Finn, Richard S. ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyorgy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Gerolami, Rene ;
Caparello, Chiara ;
Cabrera, Roniel ;
Chang, Charissa ;
Sun, Weijing ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :353-358
[8]   Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis [J].
Kan, Xuefeng ;
Liang, Bin ;
Zhou, Guofeng ;
Xiong, Bin ;
Pan, Feng ;
Ren, Yanqiao ;
Cao, Yanyan ;
Wang, Jihua ;
Yang, Fan ;
Zheng, Chuansheng .
FRONTIERS IN ONCOLOGY, 2020, 10
[9]   Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma [J].
Kim, Hwi Young ;
Park, Joong-Won ;
Joo, Jungnam ;
Jung, Se Jin ;
An, Sangbu ;
Woo, Sang Myung ;
Kim, Hyun Beom ;
Koh, Young Hwan ;
Lee, Woo Jin ;
Kim, Chang-Min .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (06) :1051-1056
[10]   Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial [J].
Kudo, Masatoshi ;
Ueshima, Kazuomi ;
Ikeda, Masafumi ;
Torimura, Takuji ;
Tanabe, Nobukazu ;
Aikata, Hiroshi ;
Izumi, Namiki ;
Yamasaki, Takahiro ;
Nojiri, Shunsuke ;
Hino, Keisuke ;
Tsumura, Hidetaka ;
Kuzuya, Teiji ;
Isoda, Norio ;
Yasui, Kohichiroh ;
Aino, Hajime ;
Ido, Akio ;
Kawabe, Naoto ;
Nakao, Kazuhiko ;
Wada, Yoshiyuki ;
Yokosuka, Osamu ;
Yoshimura, Kenichi ;
Okusaka, Takuji ;
Furuse, Junji ;
Kokudo, Norihiro ;
Okita, Kiwamu ;
Johnson, Philip James ;
Arai, Yasuaki .
GUT, 2020, 69 (08) :1492-1501
123